Ciltacabtagene Autoleucel

• Potential risk of T-cell malignancy associated with the use of chimeric antigen receptor (CAR) T cell Immunotherapies
• Secondary malignancies of T-cell origin, including chimeric antigen receptor (CAR)- positive malignancies, have been reported within weeks and up to several years following treatment of haematological malignancies with a BCMA- or CD19-directed CAR T-cell therapy.
• Patients should be monitored life-long for secondary malignancies.

1. CRS (including HLH)
2. Neurologic toxicities (including ICANS and other neurotoxicities)
3. Secondary malignancy of T-cell origin
4. Secondary malignancy of myeloid origin
5. Decrease in cell viability due to inappropriate handling or preparation of the product